Balyasny Asset Management logo

Balyasny Asset Management

North America, Illinois, United States, Chicago

Description

Balyasny Asset Management is an asset management firm dedicated to delivering consistent, uncorrelated absolute returns

Investor Profile

Balyasny Asset Management has backed more than 23 startups, with 1 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series D, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States, Sweden.
  • Strong thematic focus on FinTech, Software, Financial Services.

Stage Focus

  • Series D (26%)
  • Series C (13%)
  • Series A (13%)
  • Series F (13%)
  • Series E (9%)
  • Series G (9%)
  • Series B (9%)
  • Series Unknown (9%)

Country Focus

  • United States (96%)
  • Sweden (4%)

Industry Focus

  • Fintech
  • Software
  • Financial Services
  • Big Data
  • Health Care
  • Machine Learning
  • Finance
  • Agriculture
  • Agtech
  • E-commerce
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Balyasny Asset Management frequently co-invest with?

Baillie Gifford
Europe, Edinburgh, City of, United Kingdom, Edinburgh
Co-Investments: 3
Kleiner Perkins
North America, California, United States, Menlo Park
Co-Investments: 3
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 4
BAM Elevate
North America, New York, United States, New York
Co-Investments: 14
Battery Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 3
IVP
North America, California, United States, Menlo Park
Co-Investments: 3
NBCUniversal
North America, New York, United States, New York
Co-Investments: 3
Tiger Global Management
North America, New York, United States, New York
Co-Investments: 3
RRE Ventures
North America, New York, United States, New York
Co-Investments: 3
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 5

Which angels does Balyasny Asset Management often collaborate with?

MV
North America, Washington, United States, Seattle
Shared Deals: 2
JD
North America, California, United States, Palo Alto
Shared Deals: 1
SB
North America, California, United States, San Francisco
Shared Deals: 1
SR
North America, California, United States, Los Angeles
Shared Deals: 1
TR
North America, New York, United States, New York
Shared Deals: 1
BM
North America, Texas, United States, Austin
Shared Deals: 1
Shinji Kimura
Asia, Tokyo, Japan, Tokyo
Shared Deals: 1
RM
North America, Massachusetts, United States, Boston
Shared Deals: 1
SB
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Balyasny Asset Management?

Ovid Therapeutics

New York, New York, United States

Ovid Therapeutic's purpose is to solve intractable medical problems.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityMar 17, 2026
Amount Raised: $60,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityMar 9, 2026
Amount Raised: $85,000,000
Relmada Therapeutics

New York, New York, United States

Relmada Therapeutics is a biotech company addressing diseases of the central nervous system, with a focus on major depressive disorder.

BiotechnologyClinical TrialsPharmaceutical
Post Ipo EquityMar 9, 2026
Amount Raised: $160,000,000
Sensei Biotherapeutics

Gaithersburg, Maryland, United States

Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies.

BiotechnologyHealth DiagnosticsLife ScienceMedicalTherapeutics
Post Ipo EquityFeb 18, 2026
Amount Raised: $200,000,000
LB Pharmaceuticals

New York, New York, United States

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityFeb 5, 2026
Amount Raised: $100,000,000
Adlai Nortye

Hangzhou, Zhejiang, China

Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.

BiotechnologyHealth CareOncologyPharmaceutical
Post Ipo EquityFeb 3, 2026
Amount Raised: $140,000,000
TRex Bio

South San Francisco, California, United States

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

BioinformaticsBiopharmaBiotechnology
Series UnknownJan 27, 2026
Amount Raised: $50,000,000
Diagonal Therapeutics

Watertown, Massachusetts, United States

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

BiopharmaBiotechnologyLife ScienceMedicalTherapeutics
Series BJan 8, 2026
Amount Raised: $125,000,000
Ambros Therapeutics

Irvine, California, United States

Ambros Therapeutics is a clinical-stage biotechnology company.

BiotechnologyMedicalTherapeutics
Series ADec 16, 2025
Amount Raised: $125,000,000
Crescent Biopharma

Rockville, Maryland, United States

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

BiotechnologyHealth CareMedical Device
Post Ipo EquityDec 4, 2025
Amount Raised: $185,000,000

Find More Investors Like Balyasny Asset Management

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides